The Senior Leadership is responsible for the overall planning and operations ofthe programs and activities ofthe Robert H. Lurie Comprehensive Cancer Center. The Senior Leadership is comprised ofthe Director, Deputy Director and nine Associate Directors, and has undergone a number of changes during the current project period. Steven Rosen, MD has continued as Director since 1989, and Leonidas Platanias, MD, PhD has continued as Deputy Director since his recruitment to Northwestern in 2002. Among the Associate Directors, also continuing in their positions are (1) Jonathan Licht, MD, for Clinical Sciences Research, (2) Mr. Timothy Volpe for Administration, (3) Al B. Benson, 111, MD for Clinical Investigations, and (4) Julian Schink, MD for Clinical Affairs. Changes among the Associate Directors include (1) Thomas O'Halloran, PhD, who assumed the role of Associate Director for Basic Sciences Research in September, 2007, (2) David Cella, PhD, who assumed the role of Associate Director for Cancer Prevention and Control Research in April, 2009, (3) John Crispino, PhD, who assumed the role of Associate Director for Education and Training in August, 2008. In addition, Jill Pelling, PhD, who served as Associate Director for Translational Research since 2004, retired on August 31, 2012, and a search is currently underway for her replacement. Finally, since the time of the last review, a new Senior Leadership position of Associate Director for Equity and Minority Health has been established to further strengthen the Lurie Cancer Center's long-standing commitment to outreach and service to minority and medically under-served populations. CCSG support is requested for all Senior Leadership positions except those of Associate Director for Clinical Investigations and Associate Director for Clinical Affairs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA060553-19
Application #
8588665
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-08-01
Project End
2018-07-31
Budget Start
2013-09-16
Budget End
2014-07-31
Support Year
19
Fiscal Year
2013
Total Cost
$541,026
Indirect Cost
$189,500
Name
Northwestern University at Chicago
Department
Type
DUNS #
005436803
City
Chicago
State
IL
Country
United States
Zip Code
60611
Caralt, M; Uzarski, J S; Iacob, S et al. (2015) Optimization and critical evaluation of decellularization strategies to develop renal extracellular matrix scaffolds as biological templates for organ engineering and transplantation. Am J Transplant 15:64-75
Gach, Johannes S; Achenbach, Chad J; Chromikova, Veronika et al. (2014) HIV-1 specific antibody titers and neutralization among chronically infected patients on long-term suppressive antiretroviral therapy (ART): a cross-sectional study. PLoS One 9:e85371
Hung, Andy H; Holbrook, Robert J; Rotz, Matthew W et al. (2014) Graphene oxide enhances cellular delivery of hydrophilic small molecules by co-incubation. ACS Nano 8:10168-77
Keller, Jacob Pearson; Homma, Kazuaki; Duan, Chongwen et al. (2014) Functional regulation of the SLC26-family protein prestin by calcium/calmodulin. J Neurosci 34:1325-32
Zhao, Baobing; Keerthivasan, Ganesan; Mei, Yang et al. (2014) Targeted shRNA screening identified critical roles of pleckstrin-2 in erythropoiesis. Haematologica 99:1157-67
Jensen, Samuel A; Calvert, Andrea E; Volpert, Giora et al. (2014) Bcl2L13 is a ceramide synthase inhibitor in glioblastoma. Proc Natl Acad Sci U S A 111:5682-7
Daugherty, Rebecca L; Serebryannyy, Leonid; Yemelyanov, Alex et al. (2014) ?-Catenin is an inhibitor of transcription. Proc Natl Acad Sci U S A 111:5260-5
Anderson, Mark T; Dewenter, Lena; Maier, Berenike et al. (2014) Seminal plasma initiates a Neisseria gonorrhoeae transmission state. MBio 5:e01004-13
Cull, Elizabeth H; Altman, Jessica K (2014) Contemporary treatment of APL. Curr Hematol Malig Rep 9:193-201
Brahmer, J R; Lee, J W; Traynor, A M et al. (2014) Dosing to rash: a phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung cancer an Eastern Cooperative Oncology Group Study (E3503). Eur J Cancer 50:302-8

Showing the most recent 10 out of 316 publications